LIPS-A: Lung Injury Prevention Study With Aspirin

The primary hypothesis was that early aspirin administration will decrease the rate of developing acute lung injury during the first 7 days after presentation to the hospital.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • drug: Aspirin
  • drug: Lactose powder

Eligibility


Inclusion Criteria:

   - Adult patients (age > 18) admitted to the hospital through the emergency department
   (ED)

   - At high risk of developing acute lung injury (ALI) Lung Injury Prediction Score (LIPS)
   greater than or equal to 4

Exclusion Criteria:

   - Anti-platelet therapy on admission or within 7 days prior to admission

   - Presented to outside hospital ED > 12 hrs before arrival at site's facility

   - Inability to obtain consent within 12 hours of hospital presentation

   - Admitted for elective surgery

   - Acute lung injury prior to randomization

   - Receiving mechanical ventilation through a tracheostomy tube prior to current hospital
   admission (patient who is ventilator dependent)

   - Presence of bilateral pulmonary infiltrates on admission if he or she has a history of
   bilateral pulmonary infiltrates (as evidenced by previous x-rays) that can reasonably
   explain the current degree of pulmonary infiltrates present.

   - Presentation due to pure heart failure and no other known risk factors for ALI.

   - Allergy to aspirin or non steroidal anti inflammatory drugs (NSAIDs)

   - Bleeding disorder

   - Suspected active bleeding or judged to be at high risk for bleeding

   - Active peptic ulcer disease (within past 6 months)

   - Severe chronic liver disease

   - Inability to administer the study drug

   - Expected hospital stay < 48 hours

   - Admitted for comfort or hospice care

   - Patient, surrogate or physician not committed to full support. (Exception: a patient
   will not be excluded if he/she would receive all supportive care except for attempts
   at resuscitation from cardiac arrest)

   - Not anticipated to survive > 48 hours

   - Previously enrolled in this trial

   - Enrolled in a concomitant intervention trial

   - Pregnant or breastfeeding

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Rosemary Vojnik
650-723-7409
I'm interested

Our research team includes physicians, residents, medical students, research assistants, and volunteers. Our research topics include medical imaging, device validation,  mobile application development, and pharmaceutical trials.  

Some of the Neuro-Opthalmic concerns we investigate include Multiple Sclerosis, Optic Neuritis, IIH, and ICP.